Compare CASS & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CASS | NGNE |
|---|---|---|
| Founded | 1906 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 714.9M | 744.9M |
| IPO Year | 1996 | 2014 |
| Metric | CASS | NGNE |
|---|---|---|
| Price | $53.33 | $26.20 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $59.50 | ★ $77.88 |
| AVG Volume (30 Days) | 54.3K | ★ 247.4K |
| Earning Date | 10-22-2026 | 11-12-2026 |
| Dividend Yield | ★ 2.37% | N/A |
| EPS Growth | ★ 87.77 | 0.93 |
| EPS | ★ 1.48 | N/A |
| Revenue | ★ $190,750,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.52 | N/A |
| P/E Ratio | $36.45 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $36.07 | $15.93 |
| 52 Week High | $59.63 | $43.66 |
| Indicator | CASS | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 38.30 | 33.33 |
| Support Level | $52.75 | $24.88 |
| Resistance Level | $54.44 | $26.40 |
| Average True Range (ATR) | 0.90 | 1.93 |
| MACD | -0.03 | -0.19 |
| Stochastic Oscillator | 18.93 | 15.64 |
Cass Information Systems Inc is a provider of payment and information processing services to large manufacturing, distribution, and retail enterprises across the United States. The company provides transportation invoice rating, payment processing, auditing, accounting, and transportation information. It is also a processor and payer of energy invoices, including electricity, gas, waste, and other facility-related expenses. Additionally, the firm has a banking subsidiary, offering banking services mainly to privately held businesses in the St. Louis metropolitan area and restaurant franchises and faith-based ministries within the United States. The company operates in two reportable segments: Information Services, which generates the maximum revenue, and Banking Services.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.